Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04450732
Registration number
NCT04450732
Ethics application status
Date submitted
23/06/2020
Date registered
29/06/2020
Date last updated
5/12/2023
Titles & IDs
Public title
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
Query!
Scientific title
A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors
Query!
Secondary ID [1]
0
0
GQ1001X2101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
HER2-positive Breast Cancer
0
0
Query!
HER2-positive Biliary Tract Cancer
0
0
Query!
HER2-Positive Salivary Gland Carcinomas
0
0
Query!
HER2-Positive Advanced Solid Tumor
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Biliary tree (gall bladder and bile duct)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GQ1001
Experimental: Dose Escalation - GQ1001 will be administered intravenously every 21 days. Dose Escalation will be guided by a modified 3+3 design.
Experimental: Dose Expansion - GQ1001 at the Dose Recommended for Dose Expansion will be administered intravenously every 21 days. Dose expansion will further evaluate the MTD or DRDE in different types of malignant solid tumor in four cohorts.
Treatment: Drugs: GQ1001
anti-HER2 antibody drug conjugate
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Dose Limiting Toxicities (DLTs).
Query!
Assessment method [1]
0
0
Adverse events will be assessed using NCI CTCAE version 5.0 and will be evaluated by the investigator and the sponsor for the eligibility of DLT.
Query!
Timepoint [1]
0
0
End of Cycle 1 (21-day cycle)
Query!
Primary outcome [2]
0
0
Maximum Tolerated Dose (MTD) or Dose Recommended for Dose Expansion (DRDE)
Query!
Assessment method [2]
0
0
The SRC will also determine the MTD/DRDE based on the totality of data for all tested dose levels.
Query!
Timepoint [2]
0
0
After each cohort completes the DLT observation period (Day 1 to Day 21 after the first dose of study treatment) or has a DLT or becomes not DLT-evaluable
Query!
Secondary outcome [1]
0
0
Incidence and Severity of Adverse Events (AEs)
Query!
Assessment method [1]
0
0
Safety and Tolerability of GQ1001
Query!
Timepoint [1]
0
0
from baseline to 30 days after last dose
Query!
Secondary outcome [2]
0
0
Number of Participants with Abnormal Laboratory Values
Query!
Assessment method [2]
0
0
Safety and Tolerability of GQ1001
Query!
Timepoint [2]
0
0
rom baseline through Cycle 8 (each cycle is 21 days) and up to 30 days from treatment discontinuationafter last dose
Query!
Secondary outcome [3]
0
0
Area Under the Plasma Concentration Versus Time Curve (AUC) of GQ1001
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
through study completion, an average of 1 year
Query!
Secondary outcome [4]
0
0
Peak Plasma Concentration of GQ1001 (Cmax)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
through study completion, an average of 1 year
Query!
Secondary outcome [5]
0
0
Time at which the Cmax is Observed (Tmax)
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
through study completion, an average of 1 year
Query!
Secondary outcome [6]
0
0
Half Life of GQ1001 (T1/2)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
through study completion, an average of 1 year
Query!
Secondary outcome [7]
0
0
Mean Residence Time of GQ1001 (MRT)
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
through study completion, an average of 1 year
Query!
Secondary outcome [8]
0
0
Volume of Distribution of GQ1001 (Vd)
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
through study completion, an average of 1 year
Query!
Secondary outcome [9]
0
0
Preliminary Efficacy of GQ1001 Evaluated using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and CT of MRI scans
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
through study completion, an average of 1 year
Query!
Secondary outcome [10]
0
0
Immunogenicity
Query!
Assessment method [10]
0
0
Anti-GQ1001 antibody/anti-therapeutic antibody
Query!
Timepoint [10]
0
0
through study completion, an average of 1 year
Query!
Secondary outcome [11]
0
0
Preliminary Efficacy
Query!
Assessment method [11]
0
0
objective response rate (ORR)
Query!
Timepoint [11]
0
0
through study completion, an average of 1 year
Query!
Secondary outcome [12]
0
0
Preliminary Efficacy
Query!
Assessment method [12]
0
0
disease control rate (DCR)
Query!
Timepoint [12]
0
0
through study completion, an average of 1 year
Query!
Secondary outcome [13]
0
0
Preliminary Efficacy
Query!
Assessment method [13]
0
0
duration of response (DoR)
Query!
Timepoint [13]
0
0
through study completion, an average of 1 year
Query!
Secondary outcome [14]
0
0
Preliminary Efficacy
Query!
Assessment method [14]
0
0
progression-free survival (PFS)
Query!
Timepoint [14]
0
0
through study completion, an average of 1 year
Query!
Eligibility
Key inclusion criteria
1. Signed informed consent form and able to comply with the protocol;
2. Male and female subjects =18 years of age;
3. ECOG PS of 0 or 1, the estimated life expectancy = 3 months;
4. LVEF = 50% as determined by echocardiography (ECHO);
5. Patients must have pathologically documented advanced/unresectable or metastatic solid
tumor with HER2-positive (as defined below) that is relapsed or refractory to standard
therapy or for which there is no standard therapy and progressed. Patients must have a
least one measurable disease lesion. Tumor specimens to identify HER2 status should be
obtained within the past 6 months.
Definition of HER2-positive
- Advanced/unresectable or metastatic breast cancer: immunohistochemistry (IHC) 3+,
or IHC 2+ and in situ hybridization positive (ISH+)*;
- Advanced/unresectable or metastatic gastric or gastroesophageal junction
adenocarcinoma: IHC 3+, or IHC 2+ and ISH+*;
- Other HER2-positive advanced/unresectable or metastatic solid malignant tumor:
determined by IHC, ISH, Next Generation Sequencing, or other analysis techniques
as appropriate;
- ISH: fluorescence in situ hybridization (FISH) or dual in situ hybridization
(DISH); ISH positivity is defined as a ratio of = 2.0 for the number of HER2
gene copies to the number of signals for CEP17. ISH assay is not required
when IHC result is 3+. ISH assay should be performed to confirm HER2
positivity when IHC result is 2+.
6. Adequate organ function confirmed at screening and within 7 days before the first
treatment, as evidenced by:
Platelet count: = 100,000/mm3 ; Hemoglobin : = 9 g/dL; Absolute neutrophil count
(ANC): = 1500/mm3 ; Serum creatinine: = 1.5 × ULN (upper limit of normal), or
creatinine clearance = 60 mL/min (using Cockcroft Gault formula) ; Aspartate
aminotransferase (AST)/alanine aminotransferase (ALT) : = 2.5 × ULN (= 5 × ULN if
liver metastases are present); Total bilirubin : = 1.5 × ULN (except for patients with
Gilbert's Syndrome); Prothrombin time and activated partial thromboplastin time: = 1.5
× ULN.
7. Adequate washout period before the first treatment as defined by:
Major surgery: = 4 weeks. Radiation therapy: = 4 weeks (= 2 weeks for palliative
stereotactic radiation therapy without abdominal). Autologous transplantation: = 3
months.
Hormonal therapy: = 2 weeks or per Investigator's discretion for breast cancer
patients.
Chemotherapy or targeted therapy (including antibody drug therapy): = 3 weeks (= 2
weeks for 5 flourouracil-based agents, folinate agents, and/or weekly paclitaxel; = 2
weeks (or 5 half-lives, whichever is shorter) for tyrosine kinase inhibitors; = 4
weeks for HER2-directed biologic therapies; = 6 weeks for nitrosoureas or mitomycin
C). Immunotherapy: = 4 weeks. Strong cytochrome P450 enzyme 3A4 (CYP3A4) inhibitor: =
3 elimination half-lives . Any investigational agents or treatments: = 4 weeks.
8. Patients without a history of acquired immunodeficiency syndrome (AIDS)-defining
opportunistic infections or with a history of AIDS-defining opportunistic infections
and have not had an opportunistic infection within the past 12 months may be enrolled
per the discretion of the Investigator.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Clinically active brain metastases, defined as untreated and symptomatic, or requiring
therapy with steroids or anticonvulsants to control associated symptoms. Subjects with
treated brain metastases that are no longer symptomatic and who require no treatment
with steroids may be included in the study if they have recovered from the acute toxic
effect of chemotherapy or radiotherapy;
2. Subjects with multiple primary malignancies within 2 years, except adequately resected
non-melanoma skin cancer, curatively treated in situ disease, other solid tumors
curatively treated, or contralateral breast cancer);
3. Cardiovascular dysfunction or clinically significant cardiac disease, including but
not limited to:
- Medical history of symptomatic chronic heart failure (New York Heart Association
(NYHA) classes II-IV) or serious cardiac arrhythmia requiring treatment;
- Medical history of myocardial infarction or unstable angina within 6 months of
the first treatment;
- Corrected QT interval by Fridericia (QTcF) prolongation of > 450 milliseconds
(ms) in males and > 470 ms in females;
4. Medical history of clinically significant lung disease (e.g., interstitial pneumonia,
pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis), or patients who
are suspected to have these diseases by imaging at screening or requirement for
supplemental oxygen;
5. Known hypersensitivity to either the drug substances or inactive ingredients in the
drug product;
6. Existing Grade = 2 peripheral neuropathy;
7. Unresolved toxicities from previous anticancer therapy, defined as toxicities (other
than alopecia) not yet resolved to NCI CTCAE version 5.0, Grade = 1 or baseline.
Subjects with chronic Grade 2 toxicities may be eligible per the discretion of the
Investigator;
8. Cumulative anthracycline dose > 360 mg/m2 doxorubicin or equivalent;
9. Uncontrolled infection requiring i.v. of antibiotics, antivirals or antifungals;
10. Active infection with hepatitis C (e.g., detectable antibodies to hepatitis C virus
[HCV]) or hepatitis B (e.g., hepatitis B surface antigen [HBsAg] positive) except
subjects with occult or prior hepatitis B infection (defined as positive total
hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus
(HBV) deoxyribonucleic acid (DNA) is undetectable at the time of screening, and these
subjects must be willing to undergo monthly DNA testing and appropriate antiviral
therapy as indicated;
11. Patients with a history or current evidence of any concomitant condition, therapy, or
laboratory abnormality that, in the opinion of the Investigator, might confound the
results of the trial, interfere with the patient's participation and compliance;
12. Women who are lactating or pregnant, as confirmed by pregnancy test within 7 days
before first treatment;
13. Male and female subjects who are unwilling to use adequate contraceptive methods
(e.g., concomitant use of a spermicidal agent, barrier contraceptive, or/and
intrauterine contraceptive) during the study and for at least 7 months after the last
dose of GQ1001.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/07/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/05/2024
Query!
Actual
Query!
Sample size
Target
96
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Scientia Clinical Research Limited - Randwick
Query!
Recruitment hospital [2]
0
0
Cabrini Institute in Melbourne, Australia - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
3050 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Texas
Query!
Country [2]
0
0
China
Query!
State/province [2]
0
0
Anhui
Query!
Country [3]
0
0
China
Query!
State/province [3]
0
0
Beijing
Query!
Country [4]
0
0
China
Query!
State/province [4]
0
0
Guangdong
Query!
Country [5]
0
0
China
Query!
State/province [5]
0
0
Henan
Query!
Country [6]
0
0
China
Query!
State/province [6]
0
0
Hubei
Query!
Country [7]
0
0
China
Query!
State/province [7]
0
0
Hunan
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Liaoning
Query!
Country [9]
0
0
China
Query!
State/province [9]
0
0
Shandong
Query!
Country [10]
0
0
China
Query!
State/province [10]
0
0
Shanghai
Query!
Country [11]
0
0
China
Query!
State/province [11]
0
0
Sichuan
Query!
Country [12]
0
0
China
Query!
State/province [12]
0
0
Zhejiang
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04450732
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Yan Shi
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
0512-66526166
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04450732
Download to PDF